NKG2D receptor-ligand complex (NKG2D)

The NKG2D receptor is a transmembrane, C-type lectin-like activating receptor predominantly found on NK cells, γδ T cells, and CD8+ αβ T cells in humans and mice[1][3][4][5][6]. It forms a hexameric complex with dimers of DAP10 (and in mice, sometimes DAP12) adapter proteins, which mediate downstream signaling. The NKG2D receptor recognizes a broad array of structurally diverse ligands—such as MICA, MICB, and ULBP family proteins in humans, and Rae-1, H60 family proteins in mice—which are induced on the surface of cells experiencing stress (such as infection, malignant transformation, or cellular damage)[1][2][3][4][5][6]. Engagement of NKG2D by its ligands initiates potent immune activation, cellular cytotoxicity, and cytokine secretion, contributing to immune surveillance against cancer and infection. However, some tumors and pathogens evade immunity by shedding NKG2D ligands or downregulating receptor expression, presenting challenges for therapeutic targeting and biomarker interpretation[2][3][6]. NKG2D is being investigated as a target in cancer immunotherapy, infection control, and as a mediator of autoimmune pathology[3][6].

Other names

Killer cell lectin-like receptor subfamily K member 1KLRK1Natural killer cell receptor NKG2DNKG2DCD314 (in some contexts)NKG2D-DAP10 complex (describing receptor/adaptor association)NKG2D ligand(s): MICA, MICB, ULBP1–ULBP6, Rae-1, H60 (ligand names often grouped under NKG2D ligand)

Antagonists block NKG2D-ligand interaction, suppressing immune cell activation. Agonists or ligands enhance NKG2D-dependent activation of NK and T cells, promoting cytotoxicity against stressed or malignant cells. Immunotherapeutics (e.g., CAR-NKG2D) redirect immune effectors to target NKG2D ligand-expressing tumor or infected cells.